Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma - PubMed (original) (raw)
. 2019 Jun 13;177(7):1842-1857.e21.
doi: 10.1016/j.cell.2019.05.013. Epub 2019 May 30.
Seongyeol Park 2, Hansol Park 3, Sehui Kim 4, Jongkeun Lee 5, Junehawk Lee 6, Jeonghwan Youk 2, Kijong Yi 2, Yohan An 3, In Kyu Park 7, Chang Hyun Kang 7, Doo Hyun Chung 4, Tae Min Kim 8, Yoon Kyung Jeon 9, Dongwan Hong 5, Peter J Park 10, Young Seok Ju 11, Young Tae Kim 12
Affiliations
- PMID: 31155235
- DOI: 10.1016/j.cell.2019.05.013
Free article
Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma
Jake June-Koo Lee et al. Cell. 2019.
Free article
Abstract
Mutational processes giving rise to lung adenocarcinomas (LADCs) in non-smokers remain elusive. We analyzed 138 LADC whole genomes, including 83 cases with minimal contribution of smoking-associated mutational signature. Genomic rearrangements were not correlated with smoking-associated mutations and frequently served as driver events of smoking-signature-low LADCs. Complex genomic rearrangements, including chromothripsis and chromoplexy, generated 74% of known fusion oncogenes, including EML4-ALK, CD74-ROS1, and KIF5B-RET. Unlike other collateral rearrangements, these fusion-oncogene-associated rearrangements were frequently copy-number-balanced, representing a genomic signature of early oncogenesis. Analysis of mutation timing revealed that fusions and point mutations of canonical oncogenes were often acquired in the early decades of life. During a long latency, cancer-related genes were disrupted or amplified by complex rearrangements. The genomic landscape was different between subgroups-EGFR-mutant LADCs had frequent whole-genome duplications with p53 mutations, whereas fusion-oncogene-driven LADCs had frequent SETD2 mutations. Our study highlights LADC oncogenesis driven by endogenous mutational processes.
Keywords: SETD2; balanced rearrangement; chromoplexy; chromothripsis; complex genomic rearrangement; fusion oncogene; lung adenocarcinoma; p53; tumor initiation; whole-genome duplication.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
- Novel molecular targets for the treatment of lung cancer.
Rosell R, Karachaliou N, Arrieta O. Rosell R, et al. Curr Opin Oncol. 2020 Jan;32(1):37-43. doi: 10.1097/CCO.0000000000000590. Curr Opin Oncol. 2020. PMID: 31599770 Review. - Development of lung adenocarcinomas with exclusive dependence on oncogene fusions.
Saito M, Shimada Y, Shiraishi K, Sakamoto H, Tsuta K, Totsuka H, Chiku S, Ichikawa H, Kato M, Watanabe S, Yoshida T, Yokota J, Kohno T. Saito M, et al. Cancer Res. 2015 Jun 1;75(11):2264-71. doi: 10.1158/0008-5472.CAN-14-3282. Epub 2015 Apr 8. Cancer Res. 2015. PMID: 25855381 - From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
Plodkowski AJ, Drilon A, Halpenny DF, O'Driscoll D, Blair D, Litvak AM, Zheng J, Moskowitz CS, Ginsberg MS. Plodkowski AJ, et al. Lung Cancer. 2015 Nov;90(2):321-5. doi: 10.1016/j.lungcan.2015.09.018. Epub 2015 Sep 21. Lung Cancer. 2015. PMID: 26424208 Free PMC article. - Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Cai W, Lin D, Wu C, Li X, Zhao C, Zheng L, Chuai S, Fei K, Zhou C, Hirsch FR. Cai W, et al. J Clin Oncol. 2015 Nov 10;33(32):3701-9. doi: 10.1200/JCO.2014.58.8293. Epub 2015 Sep 28. J Clin Oncol. 2015. PMID: 26416997 Free PMC article. - The nonsmokers' and smokers' pathways in lung adenocarcinoma: Histological progression and molecular bases.
Okudela K, Matsumura M, Arai H, Woo T. Okudela K, et al. Cancer Sci. 2021 Sep;112(9):3411-3418. doi: 10.1111/cas.15031. Epub 2021 Jul 11. Cancer Sci. 2021. PMID: 34143937 Free PMC article. Review.
Cited by
- Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers.
Cheong TC, Jang A, Wang Q, Leonardi GC, Ricciuti B, Alessi JV, Di Federico A, Awad MM, Lehtinen MK, Harris MH, Chiarle R. Cheong TC, et al. Nat Commun. 2024 Jun 14;15(1):5110. doi: 10.1038/s41467-024-49499-0. Nat Commun. 2024. PMID: 38877018 Free PMC article. - Analysis of potential genetic biomarkers and molecular mechanism of smoking-related postmenopausal osteoporosis using weighted gene co-expression network analysis and machine learning.
Li S, Chen B, Chen H, Hua Z, Shao Y, Yin H, Wang J. Li S, et al. PLoS One. 2021 Sep 23;16(9):e0257343. doi: 10.1371/journal.pone.0257343. eCollection 2021. PLoS One. 2021. PMID: 34555052 Free PMC article. - Partial Response to Crizotinib in a Lung Adenocarcinoma Patient with a Novel FBXO11 (Intergenic)-ALK (Exon 20-29) Fusion.
He J, Yao Y, Quan F, Lu Z, Wang J, Gao W. He J, et al. Onco Targets Ther. 2023 Jul 7;16:535-540. doi: 10.2147/OTT.S406234. eCollection 2023. Onco Targets Ther. 2023. PMID: 37441362 Free PMC article. - STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review.
Su C, Jiang Y, Jiang W, Wang H, Liu S, Shao Y, Zhao W, Ning R, Yu Q. Su C, et al. Onco Targets Ther. 2020 Dec 4;13:12515-12519. doi: 10.2147/OTT.S282933. eCollection 2020. Onco Targets Ther. 2020. PMID: 33311990 Free PMC article. - Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways.
Soltis AR, Bateman NW, Liu J, Nguyen T, Franks TJ, Zhang X, Dalgard CL, Viollet C, Somiari S, Yan C, Zeman K, Skinner WJ, Lee JSH, Pollard HB, Turner C, Petricoin EF, Meerzaman D, Conrads TP, Hu H; APOLLO Research Network; Shriver CD, Moskaluk CA, Browning RF Jr, Wilkerson MD. Soltis AR, et al. Cell Rep Med. 2022 Nov 15;3(11):100819. doi: 10.1016/j.xcrm.2022.100819. Cell Rep Med. 2022. PMID: 36384096 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous